Tough Questions About the Value of Statin Therapy for Primary Prevention: Did JUPITER Miss the Moon?

Curtiss, Frederic R.; Fairman, Kathleen A.

doi:10.18553/jmcp.2010.16.6.417

Cited by 10 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Last, information about the full spectrum of statin AEs will provide more complete data for cost-benefit and cost-effectiveness analyses of statin use. 60 Our study has several limitations. First, we used ICD-9-CM codes for identification of baseline characteristics and statin-associated AEs, which may lack sensitivity toward some variables such as smoking and obesity.…”

Section: Discussionmentioning

confidence: 91%

Statins and Musculoskeletal Conditions, Arthropathies, and Injuries

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Statins and Musculoskeletal Conditions, Arthropathies, and Injuries

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Pletcher et al, published in 2006, estimated the annual cost for low-intensity statins at $770 [12]. Since then, prices for generic simvastatin have already fallen by 60% [17]; our results predict that at this price it would be cost-effective to treat patients at 5% 10-year risk. Others have found that at prices below $0.10 per pill, it becomes not only cost-effective but cost- saving to treat adults at all risk levels [12]; the available prices at some large retailers in the USA have already passed this threshold [18].…”

Section: Discussionmentioning

confidence: 58%

Statin cost effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States

Mitchell

Simpson

2012

BMC Res Notes

View full text Add to dashboard Cite

BackgroundThe literature on the cost-effectiveness of statin drugs in primary prevention of coronary heart disease is complex. The objective of this study is to compare the disparate results of recent cost-effectiveness analyses of statins.FindingsWe conducted a systematic review of the literature on statin cost-effectiveness. The four studies that met inclusion criteria reported varying conclusions about the cost-effectiveness of statin treatment, without a clear consensus as to whether statins are cost-effective for primary prevention. However, after accounting for each study’s assumptions about statin costs, we found substantial agreement among the studies. Studies that assumed statins to be more expensive found them to be less cost-effective, and vice-versa. Furthermore, treatment of low-risk groups became cost-effective as statins became less expensive.ConclusionsDrug price is the primary determinant of statin cost-effectiveness within a given risk group. As more statin drugs become generic, patients at low risk for coronary disease may be treated cost-effectively. Though many factors must be weighed in any medical decision, from a cost-effectiveness perspective, statins may now be considered an appropriate therapy for many patients at low risk for heart disease.

show abstract

“…28 The annual cost of optimal medical therapy for obstructive CAD (daily simvastatin, metoprolol tartrate, lisinopril, and aspirin) was estimated from the 2013 Red Book Online and other sources in the literature. 25,[29][30][31][32]36 In the base case it was assumed that payers incurred no cost for preventive therapy of daily aspirin because this is often purchased by patients over the counter; this assumption was varied in sensitivity analyses. (Additional details on cost estimation are available in the Supplementary Data in the online article at www.liebertpub.com/pop).…”

Section: Costsmentioning

confidence: 99%

Economic Utility of a Blood-Based Genomic Test for the Assessment of Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease

Hochheiser

Juusola²,

Monane³

et al. 2014

Population Health Management

View full text Add to dashboard Cite

Approximately 3 million patients with symptoms suggestive of obstructive coronary artery disease (CAD) present to primary care offices in the United States annually, resulting in approximately $6.7 billion in cardiac workup costs. Despite wide application of existing diagnostic technologies, yield of obstructive CAD at invasive coronary angiography (ICA) is low. This study used a decision analysis model to assess the economic utility of a novel gene expression score (GES) for the diagnosis of obstructive CAD. Within a representative commercial health plan's adult membership, current practice for obstructive CAD diagnosis (usual care) was compared to a strategy that incorporates the GES test (GES-directed care). The model projected the number of diagnostic tests and procedures performed, the number of patients receiving medical therapy, type I and type II errors for each strategy of obstructive CAD diagnosis, and the associated costs over a 1-year time horizon. Results demonstrate that GES-directed care to exclude the diagnosis of obstructive CAD prior to myocardial perfusion imaging may yield savings to health plans relative to usual care by reducing utilization of noninvasive and invasive cardiac imaging procedures and increasing diagnostic yield at ICA. At a 50% capture rate of eligible patients in GES-directed care, it is projected that a commercial health plan will realize savings of $0.77 per member per month; savings increase proportionally to the GES capture rate. These findings illustrate the potential value of this new blood-based, molecular diagnostic test for health plans and patients in an age of greater emphasis on personalized medicine. (Population Health Management 2014;17:287-296)

show abstract

Tough Questions About the Value of Statin Therapy for Primary Prevention: Did JUPITER Miss the Moon?

Cited by 10 publications

References 22 publications

Statins and Musculoskeletal Conditions, Arthropathies, and Injuries

Statins and Musculoskeletal Conditions, Arthropathies, and Injuries

Statin cost effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States

Economic Utility of a Blood-Based Genomic Test for the Assessment of Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease

Contact Info

Product

Resources

About